
EU approves J&J’s injectable Rybrevant with Yuhan’s Leclaza for lung cancer
Johnson & Johnson (J&J) has secured E.U. approval for its subcutaneous (SC) formulation of Rybrevant (amivantamab), to be used in combination with Yuhan Corp.'s Leclaza (lazertinib, marketed as Lazcluze in Europe) as a first-line treatment for …